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Strongyloides stercoralis aﬀects over 100 million people worldwide. Those people most susceptible to infection are those with an
immunocompromising condition, such as cancer or human immunodeﬁciency virus (HIV). Local disease may spread throughout
the body of the host, causing a condition termed disseminated strongyloidiasis. Standard treatment for Strongyloides stercoralis
infectionisoralivermectin.Wedescribeapatientwithchroniclymphocyticleukemiadiagnosedwithdisseminatedstrongyloidiasis
two weeks after initial presentation. After repeated dosing of oral ivermectin with no clinical response, serum and cerebral spinal
ﬂuid (CSF) concentrations of ivermectin were measured to assess absorption. The peak serum concentration of 49.3ng/mL
correlated with a CSF concentration of 0.14ng/mL. Despite these concentrations, the patient eventually succumbed to multi-
system organ failure. We discuss the reasons for treatment failure and explore the utility of measuring ivermectin concentrations.
Copyright © 2009 Charles E. Rose III et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Strongyloides stercoralis is a common and persistent nema-
tode infecting 100–200 million people worldwide [1].
Endemic regions for Strongyloides infection include the
Southeastern United States, eastern Europe, Southeastern
Asia, Bangladesh, Pakistan, sub-Saharan Africa, the West
Indies, and South America [2]. Human infection occurs
when infective ﬁlariform larvae penetrate through skin
which commonly happens in endemic areas when the host
bare feet come in direct contact with infested soil. This
infection without treatment may persist for up to the
lifetime of the host through its ability to endogenously
reinfect the host [3]. Most infections in immunocompetent
hosts are asymptomatic with the exception of pulmonary
and gastrointestinal symptoms during acute and chronic
infection’s [4]. When the host immunity is lost, Strongyloides
organisms can migrate through the gastrointestinal (GI)
mucosa and enter the blood stream and further disseminate
to the skin causing serpiginous and urticarial rashes, the
lungscausingedema,patchyandrapidlychanging inﬁltrates,
and even causes central nervous system involvement [4,
5]. This dissemination or hyperinfection occurs in patients
with human T-cell lymphotrophic virus type-1 infections
(HTLV-1), hematologic malignancies, or others receiving
corticosteroids, chemotherapy, or immunosuppresives for
organ transplantation [3, 4, 6–9].
OralivermectinisthetreatmentofchoiceforS.stercoralis
infection in normal [10] and immunocompromised humans
[3, 11]. However, patients with severe strongyloidiasis may
have unpredictable absorption of oral therapy because of
paralytic ileus, functional ileus, or hypoalbuminemia. [3,
7, 8, 12–14]. Unfortunately, no parenteral antihelminthic
drugs are licensed in humans, but parenteral ivermectin is
commonly used in veterinary medicine. We describe the
clinicalcourseofapatientwithdisseminatedstronglyoidiasis2 Journal of Parasitology Research
who was treated unsuccessfully with oral ivermectin. In an
attempt to determine possible causes of treatment failure,
ivermectin concentrations in plasma and CSF were ana-
lyzed.
1.CaseReport
A 59-year-old female receiving alemtuzumab for chronic
lymphocytic leukemia was admitted to a local hospi-
tal near her home in eastern Kentucky in October
2007 for altered mental status of two weeks duration.
Admission laboratory values included a white blood
count of 5900/mm3, hemoglobin of 10.4g/dL, platelets
of 120000/mm3, but absence of eosinophilia. There was
evidence of hypoalbuminemia with serum albumin of
2.4g/dL. Chest roentgenogram revealed right upper lobe
inﬁltrate, and computerized tomography of the head showed
only maxillary and ethmoid sinusitis. However, bloody
cerebrospinal ﬂuid (CSF) was found with a nontraumatic
lumbar puncture (LP) with 200000 red cells/mm3, 172
white cells/mm3, and protein of 750mg/dL. CSF studies
includingHerpessimplexvirus(HSV)polymerasechainreac-
tion (PCR), cryptococcal neoformans antigen, and bacterial
culture were negative. Despite broad-spectrum antibiotics,
thepatientencephalopathyandpulmonaryinﬁltratesdidnot
improve, and she was transferred to a tertiary hospital in
Lexington, KY, USA.
Neurologic ﬁndings at the time of transfer included a
Glasgow coma score of ﬁve, with no localization to pain.
Sputum analysis on admission revealed 1 + white blood
cells, gram-positive cocci, budding yeast ,and Strongyloides
stercoralis was identiﬁed in the ﬁlariform stage by Gram’s
stain. Oral ivermectin was started at 15 grams as a single
daily dose (∼147mcg/kg) via nasogastric tube [15, 16]. The
following day, the ivermectin dose was increased to 30 grams
per day (293mcg/kg) for three weeks to account for the
patient large body habitus (102kg) and questionable ileus
[15].
Cerebral angiography did not demonstrate aneurysm or
vasospasm. LPs 6 days apart revealed 900 and 6688 red
cells/mm3, respectively, and xanthochromic CSF from the
second LP. Protein and white cell numbers were normal both
times.
CSF studies, performed as described elsewhere, for
Cytomegalovirus (CMV) PCR, HSV PCR, Epstein-Barr virus
(EBV), JC virus (JCV) PCR, cryptococcal antigen, fungal
culture, acid-fast stain and culture, and VDRL were all
negative [17]. Stool specimens demonstrated rhabditiform
larvae, eggs, and adult S. stercoralis, with ﬁlariform larvae in
the sputum for one week after initiation of ivermectin. The
Stronglyoides antibody was 0.13IV (index value) which was
negative by laboratory reference values (<1.49 considered
negative). Lack of neurologic improvement and persistence
of S. stercoralis from the sputum led to concern for malab-
sorption of oral ivermectin. Discussion with the Food and
Drug Administration (FDA) for permission to use parenteral
veterinary ivermectin led to the measurement of plasma
and CSF ivermectin concentrations in collaboration with the
University of Iowa by high-performance liquid chromatog-
raphy [18]. The ivermectin plasma and CSF concentrations
were 49.3ng/mL and 0.14ng/mL, respectively, on day 10 of
oral ivermectin therapy. Repeat microscopy of sputum after
three weeks of therapy did not reveal organisms. Despite 22
daysoforaltherapy,thepatientshowednosignofneurologic
recovery. After discussion and permission from the surrogate
decision maker, respiratory support was withdrawn and the
patient expired. The family refused autopsy.
2. Discussion
This report describes an immunocompromised patient with
disseminated Strongyloides presenting to a community hos-
pital with two weeks of altered mental status. On transfer to
a tertiary hospital, repeat LP conﬁrmed evidence of hemor-
rhagic CSF with persistent elevation in CSF red blood cells
and xanthrochromia. S. stercoralis organisms were observed
on sputum Gram stain, which was subsequently conﬁrmed
in stool and additional sputum samples. Despite immediate
institution of ivermectin after transfer to the tertiary care
center, the patient did not improve neurologically and
expired after being transitioned to comfort care.
The patient may have died from subarachnoid hemor-
rhage and advanced encephalitis secondary to disseminated
strongyloidiasis. A previous report of S. stercoralis showed an
erythrocytic CSF predominance [14]. The hemorrhagic CSF
and xanthochromia were likely secondary to capillary rup-
ture or local inﬂammation from the host immune response.
Previous neuropathology has demonstrated the presence of
the Strongyloides larvae within capillaries, meninges, and
brain tissue in a case of disseminated strongyloidiasis after
administration of corticosteroids [19].
As in this patient, amajor diﬃculty in disseminated
strongyloidiasis is overcoming the delay in diagnosis both
because of delayed presentation for medical evaluation and
the vague symptoms that accompany disseminated disease.
However, pulmonary and gastrointestinal abnormalities
with an inﬁltrate and ileus in an immunocompromised
host should warrant consideration of the diagnosis [20].
Eosinophiliamaybemildandnonspeciﬁcandbecauseoflow
parasiteloadandirregularlarvaloutput.Microscopyofasin-
gle stool specimen not surprisingly fails to detect larvaeup to
70% of the time [5]. Strongyloides antibody may show cross-
reactivity with other helminth infections including ﬁlariasis,
Ascaris lumbricoides, and acute schistosomiasis [21, 22].
W h i l es e r o l o g yh a san e g a t i v ep r e d i c t i v ev a l u eo f9 5 % ,o u r
patient had a negative antibody test for Strongyloides despite
microscopic evidence of pulmonary and gastrointestinal
diseases [23]. It is possible that false-negative serology in our
patient was related to immunosuppression from either her
hematologic malignancy or chemotherapy.
While delay in diagnosis may have contributed to the
poor outcome, inadequate central nervous system penetra-
tion of ivermectin or ivermectin neurotoxicity may have
played a role. Bowel obstruction and ileus are commonly
describedinhyperinfectionsyndrome,andintestinalinﬂam-
mation, and bowel edema from penetration of Strongyloides
may impair absorption. In this situation the absorptionJournal of Parasitology Research 3
of oral medications is unclear, and determination of iver-
mectin concentrations appears useful to assess adequacy
of oral treatment. Hypoalbuminemia may also aﬀect the
pharmacokinetics and distribution of ivermectin. Ivermectin
is highly bound to serum albumin, and lower levels of
albumin can increase clearance of unbound drug as well as
additional eﬀects of contribution to tissue edema which can
slowabsorptionandincreasethevolumeofdistribution[14].
Increased clearance or volume of distribution may interfere
with achievement of eﬀective levels in the central nervous
system.
We were able to achieve a relatively high ivermectin
plasma level in our patient, with a daily dose of 293µg/kg.
The plasma concentrations in our patient were similar to
those observed in healthy volunteers following multiple oral
doses of 60mg given on days 1, 4, and 7 [24]. Because the
concentrations were similar to those observed in healthy
volunteers after multiple oral doses, we concluded that there
was adequate intestinal absorption and we did not further
pursue use of parenteral ivermectin [24].
Despite the higher oral ivermectin dose and achievement
of plasma concentrations that were higher than circulating
ivermectin plasma levels in previous patients, our patient
did poorly [14, 25]. Unfortunately, the eﬀective therapeutic
plasma concentration in humans is not known. Therefore,
establishing CNS penetration by measuring adequate CSF
concentrations may be important in the prediction of
outcome. At steadystate, the CSF concentration in our
patient suggested less than 1% CSF penetration of orally
administered ivermectin. Moreover, in the previous study by
Turner et al. after ﬁve daily subcutaneous ivermectin doses
of 200µg/kg, there were no detectable levels in the CSF using
the same assay methodology used in this study [25]. The
plasma levels measured after the initial dose and the seventh
daily dose were 5.8ng/mL and 12.1ng/mL, respectively, and
at 14 days steady-state plasma concentrations were 11.4–
17.4ng/mL [25].
Lastly, it seems unlikely that neurotoxic side-eﬀects of
ivermectin contributed to the poor outcome of the patient.
Adverse neurologic eﬀectsincludemydriasis,ataxia,tremors,
emesis,lethargy ,andc oma[13,24–26].However,ourpatient
was comatose prior to and after three weeks of therapy.
Moreover, healthy volunteers have tolerated single doses of
2000µg/kg, and doses up to 1091µg/kg given three times at
72-hour intervals without evidence of toxicity [24].
When orally administered ivermectin therapy fails to
produce a clinical response, alternate methods of therapy
should be considered. Subcutaneous ivermectin has been
used in numerous cases to overcome poor oral absorption
[9, 14, 25, 27, 28]. While no parenteral antihelminthic med-
ications are FDA approved for use in humans, permission
may be obtained on an individual basis to administer these
agents by alternative routes with evidence of problems of
enteral absorption.
3. Conclusion
The mortality in disseminated strongyloidiasis is high, likely
from progression of disease prior to diagnosis. Ivermectin
remains the drug of choice and is typically given orally at a
dose of 200µg / k gpe rd a yf o rt w ow e e k so ru n t i lr e s o l u t i o no f
symptoms. Becauseofpossible impaired absorption, hypoal-
buminemia, or extensive central nervous system disease,
serum concentrations may help discriminate when either
higher oral doses or parenteral ivermectin is necessary. Two
case reports as well as ours showed microscopic evidence of
Strongyloides eradication with serum concentrations ranging
from 11.4 to 49.6 (ng/dL). We were able to measure a CSF
ivermectin concentration of 0.14ng/dL, which suggests a
less than 1% central nervous system penetrance. Because
of extensive mortality, early diagnosis and treatment are
paramount in disseminated strongyloidiasis.
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